ArticleZhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences2026
Damage
Article in Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectivesSignificant interindividual differences exist in the efficacy of immunotherapy for hepatocellular carcinoma (HCC), and reliable biomarkers for predicting therapeutic response are lacking. Immunogenic cell death (ICD) participates in regulating the tumor immune microenvironment (TME) through the release of damage-associated molecular patterns (DAMPs), thereby possessing the potential to reshape the TME. DAMPs are essential for the occurrence of ICD. This study aims to address the lack of systematic evaluation of ICD-related molecular subtypes in HCC by constructing a DAMP-related molecular classification system and risk scoring model, as well as identifying hub genes regulating ICD in HCC for prognosis assessment and prediction of immunotherapy response.
methodsTranscriptomic data and clinical information from multiple cohorts, including The Cancer Genome Atlas (TCGA)-LIHC dataset, the Gene Expression Omnibus (GEO) GSE14520 dataset, and the International Cancer Genome Consortium (ICGC)-LIRI dataset, were integrated. Unsupervised consensus clustering analysis of 40 DAMP-related genes was performed to identify molecular subtypes of HCC, followed by functional analyses and identification of activated signaling pathways in each subtype. Prognosis-related genes were screened from differentially expressed genes using univariate Cox regression analysis, and a DAMP scoring model was established through least absolute shrinkage and selection operator (LASSO) regression and stepwise Cox regression analyses. The ESTIMATE algorithm was used to evaluate TME characteristics, and the CIBERSORT algorithm was applied to analyze immune cell infiltration levels in HCC. Time-dependent receiver operating characteristic (ROC) curve analysis was used to evaluate the prognostic predictive performance of the DAMP score and compare it with clinical characteristics and previously published messenger RNA (mRNA) biomarkers. Weighted gene co-expression network analysis (WGCNA) was used to identify hub genes associated with the DAMP score. Immunohistochemistry (IHC) staining was performed to validate differential expression of hub genes between tumor and normal tissues. In vitro experiments, including cell counting kit-8 (CCK-8) assays and wound-healing assays, were conducted to investigate the role of hub genes in HCC. Flow cytometry was used to detect apoptosis levels and evaluate sensitivity to the ICD inducer 5-fluorouracil (5-FU).
resultsUnsupervised consensus clustering analysis showed that HCC patients could be classified into 2 subgroups, namely low-DAMP-score and high-DAMP-score groups, based on the expression profiles of DAMP-related genes. Patients in the low-DAMP-score group had longer overall survival and exhibited higher immune cell infiltration, particularly CD8⁺ T-cell infiltration (all
conclusionsThe prognostic risk scoring model constructed based on DAMP-related genes can effectively stratify HCC patients and is closely associated with characteristics of the tumor immune microenvironment. The DAMP scoring model established in this study may be used for prognostic evaluation and prediction of immunotherapy efficacy in HCC and demonstrated stable predictive performance across multiple cohorts. As a hub gene in this DAMP scoring model,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.